Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Moodys
US Department of Justice
Federal Trade Commission
Cantor Fitzgerald
Teva
Citi
Argus Health
US Army
Mallinckrodt

Generated: August 18, 2017

DrugPatentWatch Database Preview

Olopatadine hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for olopatadine hydrochloride and what is the scope of olopatadine hydrochloride patent protection?

Olopatadine hydrochloride
is the generic ingredient in five branded drugs marketed by Somerset Theraps Llc, Zach System Spa, Wockhardt Ltd, Aurobindo Pharma Ltd, Akorn Inc, Novartis Pharms Corp, Barr Labs Inc, Apotex Inc, Usv North America, and Perrigo Israel, and is included in fourteen NDAs. There are six patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Olopatadine hydrochloride has fifty-three patent family members in twenty-four countries.

There are seventeen drug master file entries for olopatadine hydrochloride. Sixteen suppliers are listed for this compound. There are five tentative approvals for this compound.

Summary for Generic Name: olopatadine hydrochloride

Tradenames:5
Patents:6
Applicants:10
NDAs:14
Drug Master File Entries: see list17
Suppliers / Packagers: see list16
Bulk Api Vendors: see list73
Clinical Trials: see list2,274
Patent Applications: see list2,716
Therapeutic Class:Ophthalmic Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:olopatadine hydrochloride at DailyMed

Pharmacology for Ingredient: olopatadine hydrochloride

Tentative approvals for OLOPATADINE HYDROCHLORIDE

Applicant Application No. Strength Dosage Form
► Subscribe► Subscribe0.2% BASESOLUTION; OPHTHALMIC
► Subscribe► Subscribe0.1%SOLUTION; OPHTHALMIC
► Subscribe► Subscribe0.1%SOLUTION/DROPS; OPHTHALMIC
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zach System Spa
OLOPATADINE HYDROCHLORIDE
olopatadine hydrochloride
SOLUTION/DROPS;OPHTHALMIC204706-001Dec 7, 2015ATRXNoNo► Subscribe► Subscribe► Subscribe
Perrigo Israel
OLOPATADINE HYDROCHLORIDE
olopatadine hydrochloride
SPRAY, METERED;NASAL202853-001Jan 31, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma Ltd
OLOPATADINE HYDROCHLORIDE
olopatadine hydrochloride
SOLUTION/DROPS;OPHTHALMIC204812-001Dec 18, 2015ATRXNoNo► Subscribe► Subscribe► Subscribe
Akorn Inc
OLOPATADINE HYDROCHLORIDE
olopatadine hydrochloride
SOLUTION/DROPS;OPHTHALMIC204532-001Jan 10, 2017ATRXNoNo► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
PAZEO
olopatadine hydrochloride
SOLUTION/DROPS;OPHTHALMIC206276-001Jan 30, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: olopatadine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp
PATADAY
olopatadine hydrochloride
SOLUTION/DROPS;OPHTHALMIC021545-001Dec 22, 2004► Subscribe► Subscribe
Novartis Pharms Corp
PATANOL
olopatadine hydrochloride
SOLUTION/DROPS;OPHTHALMIC020688-001Dec 18, 1996► Subscribe► Subscribe
Novartis Pharms Corp
PATANOL
olopatadine hydrochloride
SOLUTION/DROPS;OPHTHALMIC020688-001Dec 18, 1996► Subscribe► Subscribe
Novartis Pharms Corp
PATANOL
olopatadine hydrochloride
SOLUTION/DROPS;OPHTHALMIC020688-001Dec 18, 1996► Subscribe► Subscribe
Novartis Pharms Corp
PATADAY
olopatadine hydrochloride
SOLUTION/DROPS;OPHTHALMIC021545-001Dec 22, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: olopatadine hydrochloride

Country Document Number Estimated Expiration
South Korea20160144507► Subscribe
Poland367780► Subscribe
Austria295149► Subscribe
Russian Federation2613715► Subscribe
European Patent Office3045172► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: OLOPATADINE HYDROCHLORIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0040France► SubscribePRODUCT NAME: OLOPATADINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/02/217/001 20020517
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Teva
Moodys
AstraZeneca
Baxter
Healthtrust
Chinese Patent Office
Mallinckrodt
Merck
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot